MD Newsline
In this episode of MD Newsline, Dr. Dillon Bannis, an OB-GYN practitioner based in the South Side of Chicago, shares his insights on the evolving challenges and innovations in obstetric and gynecological care. Dr. Bannis explores how listening, collaboration, and technology are reshaping the patient experience—from prenatal care and delivery practices to addressing health disparities and integrating AI into medicine.
With a strong emphasis on patient-centered communication, interdisciplinary col
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Wanda Averhart, a general pediatrician and obesity medicine specialist, explores the complex causes and lifelong impacts of childhood obesity, emphasizing how early feeding practices, maternal health, and social disparities shape children's long-term outcomes.
Dr. Averhart provides a comprehensive look at how environmental, cultural, and biological factors contribute to rising obesity rates among children—especially in underrepresented communities. She discuss
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Shaina A. Rozell, a hematologist-oncologist at Affiliate Oncology in Chicago, Illinois, explores the rapidly advancing field of multiple myeloma treatment. She discusses how quadruplet therapies, MRD monitoring, and novel immunotherapies like bispecific antibodies and CAR-T are transforming outcomes for patients. Dr. Rozell also examines disparities in access to care, the growing role of community practices in clinical trials, and the balance between extending survival
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Tonia L. Farmer, a board-certified otolaryngologist and head & neck surgeon, discusses the gaps in ENT care, the growing impact of HPV-related cancers, and the importance of education and early detection in improving outcomes—particularly for underserved communities. Drawing from years of practice, Dr. Farmer explores how social, behavioral, and environmental factors shape ENT health and shares insights on emerging research and technologies revolutionizing the field.
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Christopher Kaisa, Assistant Professor of Medicine in the Section of Gastroenterology, Hepatology, and Nutrition at the University of Chicago Medicine, provides an in-depth discussion on Metabolic Dysfunction-Associated Steatohepatitis (MASH) and the evolving strategies for its management. He explains the latest non-invasive diagnostic tools, pharmacologic advancements, and the importance of multidisciplinary care in improving outcomes for patients with metabolic liver
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Rachael Sood, a diabetes nurse practitioner and certified diabetes care and education specialist from New Orleans, Louisiana, shares her insights from the 85th American Diabetes Association Scientific Sessions. As the founder of The Diabetes Collective, Dr. Sood discusses the evolution of diabetology—a specialized field focused solely on the identification, treatment, and management of diabetes across all patient populations.
info_outline
MD Newsline
In this episode of MD Newsline, Dr. Martin Kaiser, Consultant Hematologist at the Royal Marsden Hospital and Professor of Hematology at the Institute of Cancer Research, London, discusses groundbreaking advances in the diagnosis and management of high-risk multiple myeloma. Drawing insights from the OptiMUM trial and related studies, Dr. Kaiser explores how genetic profiling, long-term treatment intensity, and personalized approaches are transforming patient outcomes. He also examines the challenges of t
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Mark R. Litzow, Professor of Medicine at the Mayo Clinic in Rochester, Minnesota, discusses the groundbreaking findings from the ECOG-ACRIN E1910 trial and the evolving role of immunotherapy in acute lymphoblastic leukemia (ALL). He explores how real-world evidence complements clinical trials, the challenges of standardizing measurable residual disease (MRD) testing, and the future of personalized treatment strategies in hematologic malignancies.
Dr. Litzow shares deep
info_outlineMD Newsline
In this episode of MD Newsline, Dr. Sassan Mirfakhraee, adult endocrinologist and associate professor at the University of Texas Southwestern Medical Center, shares groundbreaking insights into the management of adrenal insufficiency. At the Endocrine 2025 conference, Dr. Mirfakhraee presented his research on utilizing insulin pumps to deliver hydrocortisone—an innovative off-label approach that is showing promising results for patients who remain symptomatic on oral therapy.
He explains how thi
info_outlineMD Newsline
In this episode of MD Newsline, we welcome Dr. Emily Zboril, a PhD candidate at Virginia Commonwealth University, to discuss her groundbreaking research on ER-positive breast cancer with bone metastasis. Emily sheds light on the unique challenges of treating this condition, the role of the bone microenvironment, and how novel therapies like lazophoxifene may change the landscape of care.
She explains how endocrine therapies currently used to block estrogen signaling often worsen bone fragility, leading t
info_outlineIn this episode of MD Newsline, Dr. Andreas Hochhaus, Professor of Internal Medicine, Hematology, and Oncology at the Comprehensive Cancer Center in Jena, Germany, shares his expertise on the evolution of chronic myeloid leukemia (CML) therapies. He reflects on decades of progress in CML treatment, from interferon to targeted TKIs, and highlights the importance of tolerability, patient-centered care, and innovative trial data shaping the future of CML management.
Episode HighlightsThe Evolution of CML Therapy Dr. Hochhaus outlines the transformation of CML treatment, from interferon to imatinib, and the development of second- and third-generation TKIs. He emphasizes advances in efficacy while acknowledging the persistent challenge of drug resistance.
Managing Tolerability and Side Effects Toxicities such as cardiovascular, hepatic, and renal complications remain key concerns. Dr. Hochhaus discusses how improving tolerability is central to optimizing patient quality of life.
Enliven-01 Trial He highlights the unique pharmacologic profile of Enliven-01, with fewer off-target effects and encouraging safety data, underscoring its potential as a novel therapeutic option.
ASCIMINIB as a New Standard Comparing ASCIMINIB with nilotinib, Dr. Hochhaus explains its superior tolerability and efficacy, positioning it as a game-changer in frontline CML therapy.
Patient-Centered Care and Future Directions Dr. Hochhaus stresses the importance of shared decision-making, molecular monitoring, and pathways to treatment-free remission, while also pointing to challenges such as additional gene mutations and resistance mechanisms.
Key TakeawayThe future of CML treatment lies in balancing efficacy, safety, and patient quality of life. With emerging therapies like Enliven-01 and ASCIMINIB, clinicians can provide more personalized and effective care while expanding opportunities for treatment-free remission.
ResourcesWebsite: https://mdnewsline.com/ Newsletter: https://mdnewsline.com/subscribe/
Connect with Dr. Andreas HochhausHosted on Acast. See acast.com/privacy for more information.